Table of contents of the consolidated version
List of corrigenda and amendments carried out so far
Table of contents of the regulation
Text of regulation
List of Annexes
Annex I GENERAL PROVISIONS FOR ASSESSING SUBSTANCES AND PREPARING CHEMICAL SAFETY REPORTS
Annex II GUIDE TO THE COMPILATION OF SAFETY DATA SHEETS
Annex III CRITERIA FOR SUBSTANCES REGISTERED IN QUANTITIES BETWEEN 1 AND 10 TONNES
Annex IV EXEMPTIONS FROM THE OBLIGATION TO REGISTER IN ACCORDANCE WITH ARTICLE 2(7)(a)
Annex V EXEMPTIONS FROM THE OBLIGATION TO REGISTER IN ACCORDANCE WITH ARTICLE 2(7)(b)
Annex VI INFORMATION REQUIREMENTS REFERRED TO IN ARTICLE
Annex VII STANDARD INFORMATION REQUIREMENTS FOR SUBSTANCES MANUFACTURED OR IMPORTED IN QUANTITIES OF ONE TONNE OR MORE
Annex VIII STANDARD INFORMATION REQUIREMENTS FOR SUBSTANCES MANUFACTURED OR IMPORTED IN QUANTITIES OF 10 TONNES OR MORE
Annex IX STANDARD INFORMATION REQUIREMENTS FOR SUBSTANCES MANUFACTURED OR IMPORTED IN QUANTITIES OF 100 TONNES OR MORE
Annex X STANDARD INFORMATION REQUIREMENTS FOR SUBSTANCES MANUFACTURED OR IMPORTED IN QUANTITIES OF 1 000 TONNES OR MORE
Annex XI GENERAL RULES FOR ADAPTATION OF THE STANDARD TESTING REGIME SET OUT IN ANNEXES VII TO X
Annex XII GENERAL PROVISIONS FOR DOWNSTREAM USERS TO ASSESS SUBSTANCES AND PREPARE CHEMICAL SAFETY REPORTS
Annex XIII CRITERIA FOR THE IDENTIFICATION OF PERSISTENT, BIOACCUMULATIVE AND TOXIC SUBSTANCES, AND VERY PERSISTENT AND VERY BIOACCUMULATIVE SUBSTANCES
Annex XIV LIST OF SUBSTANCES SUBJECT TO AUTHORISATION
Annex XV DOSSIERS
Annex XVI SOCIO-ECONOMIC ANALYSIS
Annex XVII RESTRICTIONS ON THE MANUFACTURE, PLACING ON THE MARKET AND USE OF CERTAIN DANGEROUS SUBSTANCES, MIXTURES AND ARTICLES
Chemicals legislation is quite a vivid regulatory arena. As is the case in the science of Chemistry itself, there is also no standstill in chemicals legislation. Most of the relevant regulations are subject to chronic revisions.
In order to keep up with the actual legislation beyond the efforts of a looseleaf-binder the series
CSL: Consolidated Substances Legislation has been created.
It offers a firm outline regarding the different fields of substances legislation (besides the general substances legislation like REACH also cosmetics legislation, etc.) and provides users with the relevant legislative texts in an actual and consolidated manner. I.e. starting from the original regulation all modifications can be found at their respective position within the legal text. Therefore, the need for a detailed compilation of each and any corrigendum, amendment and adaptation to the technical progress can be reduced to a minimum.
The area of substances legislation is both a fascinating and demanding legal field that can hardly be compared to any other, as its regulations create direct effects on everyone.
The series CSL offers a new access to its origins (cf. www.merenyi.net). Schoeneck, Germany, July 2014
In June 2007 the REACH regulation entered into force. As symbolized by its acronym it created the legal base for the most important mechanisms in chemicals legislation, registration, evaluation, authorisation and restriction of chemicals.
Until beginning of 2014 these mechanisms led to the following results:
Registration means the transmission of data about the effects of a certain substance on man and environment. Extent and details of the needed data are defined in the Annexes of the REACH regulation and depend on the production/import volume of a substance.
The registration obligation has been newly implemented with REACH. Subject to the exemptions from registration (Art. 2 and Annex IV and V REACH), it applies to any substance produced or imported in amounts starting with one tonne per year and manufacturer/importer. According to its entry into force “phase by phase” (Art. 23) the following substances had to be registered with the European Chemicals Agency (ECHA) until
- the end of phase 1 (December 2010)
- all CMR substances in amounts starting with one tonne/year
- all substances with a certain toxicity to aquatic organisms in amounts starting with 100 tonnes/year
- all substances of high production volumes (i. e. in amounts starting with 1,000 tonnes/year)
- the end of phase 2 (June 2013)
- all remaining substances independent from their hazard profile in amounts starting with 100 tonnes/year.
Up to now, more than 12,000 substances have been registered (cf. the registration statistics http://echa.europa.eu/de/information-on- chemicals/registration-statistics and the list of registered substances http://echa.europa.eu/de/information-on-chemicals/registered-substances at ECHA’s webpage).
Substances which are subject to the registration obligation are not marketable in Europe unless they are registered with ECHA, i.e. they must not be produced, imported or utilized for any use without the needed registration. Despite this aspect in the context of Civil Law, violation of the registration obligation can lead to different sanctions in the different Member States. E. g. in Germany, production and distribution of substances unregistered contrary to duty can be prosecuted with a prison sentence of up to two years (§ 27b sec. 1 No. 1 German Chemicals Act; for more sanctions valid in Germany cf. the new Chemicals Sanctions Ordinance of April 24, 2014).
From the multiplicity of registered substances those substances which give cause for serious concern and therefore require a closer examination (substance evaluation) will be selected according to the specifications of the regulation (Art. 44). Such a concern can result from an already known adverse effect of a substance. Moreover, the selection will consider to what extent man and environment are exposed to the relevant substance (exposition) and also its amounts of production and use as very high production amounts can indicate a potential wide range risk of a substance.
This selection (prioritisation) is made by ECHA in collaboration with the 27 EU Member States. It is established within the so called CoRAP (Community Rolling Action Plan). The first CoRAP listed 90 substances. The actual version now contains 210 substances following its last update which takes place in March of every year (cf. http://echa.europa.eu/de/information-on- chemicals/evaluation/community-rolling-action-plan/corap-list-of-substances).
Substances listed in the CoRAP will undergo a closer evaluation by the 27 EU Member States. This procedure can result in certain provisions under the authorisation- or restriction scheme.
Besides the substance evaluation, REACH also knows two more regulation mechanisms which are also called “evaluation” (cf. http://echa.europa.eu/regulations/reach/evaluation).
The authorisation mechanism probably is the most powerful instrument of chemicals legislation. It has newly been introduced with REACH. Only those substances can come under the scope of the authorisation regime which show certain extremely problematic effects, e. g. carcinogenic, mutagenic or toxic to reproduction (cf. Art. 57).
In a first step these substances can be declared so called “substances of very high concern“ (SVHCs). This declaration is executed within a multi step process (http://echa.europa.eu/de/addressing-chemicals-of- concern/authorisation/substances-of-very-high-concern-identification), beginning with the inclusion of a certain substance in the so called “candidate list” (http://echa.europa.eu/de/candidate-list-table).
Substances which at the end of this process are declared SVHCs, are then included in Annex XIV REACH. Currently, there are 151 substances listed on the candidate list, and 22 substances in Annex XIV.
Substances listed in Annex XIV are subject to an “authorisation obligation“. This means they are generally no longer allowed to be marketed and used. The European Commission can grant detailed and narrow exemptions (authorisation) from this general ban only applying a complex application procedure. A SVHC may then also, inside the EU, be utilized again for very specific uses.
The grant of an authorisation however requires the applicant’s demonstration that the risks of using a SVHC are adequately controlled (1st alternative) or that the significance of the substance outweighs the risks (2nd alternative). Finding the right balance in the case of the 2nd Alternative is subject to the Socio Economic Analysis (SEA) procedure that finally focuses on the original aim of the authorisation scheme, the substitution of SVHCs by less harmful alternatives. In the end all SVHCs should become substituted this way.
Restriction in the context of the REACH regulation means “any condition for or prohibition of the manufacture, use or placing on the market“ of a certain substance (Art. 3 Nr. 31). Restriction under REACH therefore differs from restrictions under the former Chemicals legislation. At that time the restriction directive (76/769/EEC) did not refer to any production but mostly to single specific uses of a substance. Moreover, because of its legal nature as a directive, restrictions based on the former mechanism needed a transformation into the national law of the single Member States. REACH as a regulation, on the contrary, is binding in its entirety and directly applicable in all Member States.
As distinguished from substances within the authorisation scheme which are generally banned, use and marketing of substances in the REACH restriction scheme stays basically permitted. Merely those actions which are explicitly described in Annex XVII are prohibited.
Many restrictions derived from the old system were transferred into the new restriction scheme under REACH. Together with the newly established restrictions under REACH they are listed in Annex XVII which is the most extensive Annex of the regulation.
The stepwise implementation of the different REACH obligations will also extend into the following years.
As a next milestone, 01 June 2018 is on the horizon when every substance on the European market in amounts starting with 1 tonne/year and producer/importer has to be registered independently of its hazard profile. Thus, this third registration phase will also cover those substances which exist in comparatively low tonnages only and/or show properties which are deemed to be less or not hazardous at all.
Regarding similar experiences in the field of the biocides and plant protection products regulations, some expect a decline in the number of marketable substances due to the costs of a REACH registration which in this phase may affect small and medium enterprises (SME) in a more direct way than in the previous registration phases.
Finally, after this registration phase the core question will appear, asking for the proportionality between all efforts made for realizing the REACH system and the objectives achieved. Presumably, the answer to this question will require a more precise contouring of the equivalent premises under which the REACH regulation can be seen as a success story at all. Because of its enormous complexity no general answer seems to be possible. Much more, a detailed consideration of the different REACH mechanisms seems to be necessary.
Thus, aiming at an adequate evaluation of the REACH regulation, all stakeholders are already now called upon to describe the conditions under which they would see the equivalent REACH mechanisms as a success.
The series Consolidated Substances Legislation (CSL) will also be reporting on this theme.
Consolidated version of
REGULATION (EC) No 1907/2006 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL
of 18 December 2006
concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing
Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and
Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC
last amended by
Council Regulation (EU) No 517/2013 of 13 May 2013
Consolidation implies the integration of Community legislation, i.e. their basic instruments, amendments and corrections in one single, non-official document.
Therefore, this document is only be intended as documentation tool.
Only European Union legislation printed in
the paper edition of the
Official Journal of the European Union (OJ)
and the electronic edition thereof (e-OJ) accordingly is deemed authentic.
(not reprinted here - Cf. the information about corresponding web links at the end of the book).
Origin of the following reproduced legal text:
© European Union, http://eur-lex.europa.eu/.
This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents
B C1 REGULATION (EC) No 1907/2006 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 18 December 2006
concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC
(Text with EEA relevance)
(OJ L 396, 30.12.2006, p. 1)
Abbildung in dieser Leseprobe nicht enthalten
REGULATION (EC) No 1907/2006 OF THE EUROPEAN
PARLIAMENT AND OF THE COUNCIL of 18 December 2006
concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation
(EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC
(Text with EEA relevance)
THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION,
Having regard to the Treaty establishing the European Community, and in particular Article 95 thereof,
Having regard to the proposal from the Commission,
Having regard to the opinion of the European Economic and Social Committee 1,
Having regard to the opinion of the Committee of the Regions 2,
Acting in accordance with the procedure laid down in Article 251 of the Treaty 3,
(1) This Regulation should ensure a high level of protection of
human health and the environment as well as the free movement of substances, on their own, in M3 mixtures and in articles, while enhancing competitiveness and innovation. This Regulation should also promote the development of alter native methods for the assessment of hazards of substances.
(2) The efficient functioning of the internal market for substances can be achieved only if requirements for substances do not differ significantly from Member State to Member State.
(3) A high level of human health and environmental protection should be ensured in the approximation of legislation on substances, with the goal of achieving sustainable development. That legislation should be applied in a non-discriminatory manner whether substances are traded on the internal market or interna tionally in accordance with the Community's international commitments.
(4) Pursuant to the implementation plan adopted on 4 September 2002 at the Johannesburg World Summit on sustainable develop ment, the European Union is aiming to achieve that, by 2020, chemicals are produced and used in ways that lead to the mini misation of significant adverse effects on human health and the environment.
(5) This Regulation should apply without prejudice to Community workplace and environment legislation.
(6) This Regulation should contribute to fulfilment of the Strategic Approach to International Chemical Management (SAICM) adopted on 6 February 2006 in Dubai.
(7) To preserve the integrity of the internal market and to ensure a high level of protection for human health, especially the health of workers, and the environment, it is necessary to ensure that manufacturing of substances in the Community complies with Community law, even if those substances are exported.
(8) Special account should be taken of the potential impact of this Regulation on small- and medium-sized enterprises (SMEs) and the need to avoid any discrimination against them.
(9) The assessment of the operation of the four main legal instruments governing chemicals in the Community, i.e. Council Directive 67/548/EEC of 27 June 1967 on the approx imation of the laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances 1, Council Directive 76/769/EEC of 27 July 1976 on the approximation of the laws, regulations and administrative provisions of the Member States relating to restrictions on the marketing and use of certain dangerous substances and preparations 2, Directive 1999/45/EC of the European Parliament and of the Council of 31 May 1999 concerning the approximation of the laws, regulations and admin istrative provisions of the Member States relating to the classifi cation, packaging and labelling of dangerous preparations 3 and Council Regulation (EEC) No 793/93 of 23 March 1993 on the evaluation and control of the risks of existing substances 4, identified a number of problems in the functioning of Community legislation on chemicals, resulting in disparities between the laws, regulations and administrative provisions in Member States directly affecting the functioning of the internal market in this field, and the need to do more to protect public health and the environment in accordance with the precautionary principle.
(10) Substances under customs supervision which are in temporary storage, in free zones or free warehouses with a view to re- exportation or in transit are not used within the meaning of this Regulation and should therefore be excluded from its scope. The carriage of dangerous substances and of dangerous M3 mixtures by rail, road, inland waterways, sea or air should also be excluded from its scope as specific legislation already applies to such carriage.
(11) To ensure workability and to maintain the incentives for waste recycling and recovery, wastes should not be regarded as substances, M3 mixtures or articles within the meaning of this Regulation.
(12) An important objective of the new system to be established by this Regulation is to encourage and in certain cases to ensure that substances of high concern are eventually replaced by less dangerous substances or technologies where suitable econom ically and technically viable alternatives are available. This Regu lation does not affect the application of Directives on worker protection and the environment, especially Directive 2004/37/EC of the European Parliament and of the Council of 29 April 2004 on the protection of workers from the risks related to exposure to carcinogens or mutagens at work (Sixth individual Directive within the meaning of Article 16(1) of Council Directive 89/391/EEC) 1 and Council Directive 98/24/EC of 7 April 1998 on the protection of the health and safety of workers from the risks related to chemical agents at work (four teenth individual Directive within the meaning of Article 16(1) of Directive 89/391/EEC) 2 under which employers are required to eliminate dangerous substances, wherever technically possible, or to substitute dangerous substances with less dangerous substances.
(13) This Regulation should apply without prejudice to the prohi bitions and restrictions laid down in Council Directive 76/768/EEC of 27 July 1976 on the approximation of the laws of the Member States relating to cosmetic products 3 in so far as substances are used and marketed as cosmetic ingredients and are within the scope of this Regulation. A phase-out of testing on vertebrate animals for the purpose of protecting human health as specified in Directive 76/768/EEC should take place with regard to the uses of those substances in cosmetics.
(14) This Regulation will generate information on substances and their uses. Available information, including that generated by this Regulation, should be used by the relevant actors in the appli cation and implementation of appropriate Community legislation, for example that covering products, and Community voluntary instruments, such as the eco-labelling scheme. The Commission should consider in the review and development of relevant Community legislation and voluntary instruments how infor mation generated by this Regulation should be used, and examine possibilities for establishing a European quality mark.
(15) There is a need to ensure effective management of the technical, scientific and administrative aspects of this Regulation at Community level. A central entity should therefore be created to fulfil this role. A feasibility study on the resource requirements for this central entity concluded that an independent central entity offered a number of long-term advantages over other options. A European Chemicals Agency (hereinafter referred to as the Agency) should therefore be established.
(16) This Regulation lays down specific duties and obligations on manufacturers, importers and downstream users of substances on their own, in M3 mixtures and in articles. This Regu lation is based on the principle that industry should manufacture, import or use substances or place them on the market with such responsibility and care as may be required to ensure that, under reasonably foreseeable conditions, human health and the environ ment are not adversely affected.
(17) All available and relevant information on substances on their own, in M3 mixtures and in articles should be collected to assist in identifying hazardous properties, and recommen dations about risk management measures should systematically be conveyed through supply chains, as reasonably necessary, to prevent adverse effects on human health and the environment. In addition, communication of technical advice to support risk management should be encouraged in the supply chain, where appropriate.
(18) Responsibility for the management of the risks of substances should lie with the natural or legal persons that manufacture, import, place on the market or use these substances. Information on the implementation of this Regulation should be easily accessible, in particular for SMEs.
(19) Therefore, the registration provisions should require manufac turers and importers to generate data on the substances they manufacture or import, to use these data to assess the risks related to these substances and to develop and recommend appro priate risk management measures. To ensure that they actually meet these obligations, as well as for transparency reasons, regis tration should require them to submit a dossier containing all this information to the Agency. Registered substances should be allowed to circulate on the internal market.
(20) The evaluation provisions should provide for follow-up to regis tration, by allowing for checks on whether registrations are in compliance with the requirements of this Regulation and if necessary by allowing for generation of more information on the properties of substances. If the Agency in cooperation with the Member States considers that there are grounds for considering that a substance constitutes a risk to human health or the environment, the Agency should, after having included the substance in the Community rolling action plan for substance evaluation, relying on the competent authorities of Member States, ensure that this substance is evaluated.
(21) Although the information yielded on substances through evaluation should be used in the first place by manufacturers and importers to manage the risks related to their substances, it may also be used to initiate the authorisation or restrictions procedures under this Regulation or risk management procedures under other Community legislation. Therefore it should be ensured that this information is available to the competent auth orities and may be used by them for the purpose of such procedures.
(22) The authorisation provisions should ensure the good functioning of the internal market while assuring that the risks from substances of very high concern are properly controlled. Author isations for the placing on the market and use should be granted by the Commission only if the risks arising from their use are adequately controlled, where this is possible, or the use can be justified for socio-economic reasons and no suitable alternatives are available, which are economically and technically viable.
(23) The restriction provisions should allow the manufacturing, placing on the market and use of substances presenting risks that need to be addressed, to be made subject to total or partial bans or other restrictions, based on an assessment of those risks.
(24) In preparation for this Regulation, the Commission has launched REACH Implementation Projects (RIPs), involving relevant experts from stakeholder groups. Some of those projects aim at developing draft guidelines and tools which should help the Commission, the Agency, Member States, manufacturers, importers and downstream users of substances to fulfil, in concrete terms, their obligations under this Regulation. This work should enable the Commission and the Agency to make available appropriate technical guidance, in due time, with regard to the deadlines introduced by this Regulation.
(25) The responsibility to assess the risks and hazards of substances should be given, in the first place, to the natural or legal persons that manufacture or import substances, but only when they do so in quantities exceeding a certain volume, to enable them to carry the associated burden. Natural or legal persons handling chemicals should take the necessary risk management measures in accordance with the assessment of the risks of substances and pass on relevant recommendations along the supply chain. This should include describing, documenting and notifying in an appropriate and transparent fashion the risks stemming from the production, use and disposal of each substance.
(26) In order to undertake chemical safety assessments of substances effectively, manufacturers and importers of substances should obtain information on these substances, if necessary by performing new tests.
(27) For purposes of enforcement and evaluation and for reasons of transparency, the information on these substances, as well as related information, including on risk management measures, should normally be submitted to authorities.
(28) Scientific research and development normally takes place in quantities below one tonne per year. There is no need to exempt such research and development because substances in those quantities do not have to be registered in any case. However, in order to encourage innovation, product and process oriented research and development should be exempted from the obligation to register for a certain time period where a substance is not yet intended to be placed on the market to an indefinite number of customers because its application in M3 mixtures or articles still requires further research and development performed by the potential registrant himself or in cooperation with a limited number of known customers. In addition, it is appropriate to provide for a similar exemption to downstream users using the substance for the purposes of product and process oriented research and development, provided that the risks to human health and the environment are adequately controlled in accordance with the requirements of legislation for the protection of workers and the environment.
(29) Since producers and importers of articles should be responsible for their articles, it is appropriate to impose a registration requirement on substances which are intended to be released from articles and have not been registered for that use. In the case of substances of very high concern which are present in articles above tonnage and concentration thresholds, where exposure to the substance cannot be excluded and where the substance has not been registered by any person for this use, the Agency should be notified. The Agency should also be empowered to request that a registration be submitted if it has grounds for suspecting that the release of a substance from the article may present a risk to human health or the environment and the substance is present in those articles in quantities totalling over one tonne per producer or importer per year. The Agency should consider the need for a proposal for a restriction where it considers that the use of such substances in articles poses a risk to human health or the environment that is not adequately controlled.
(30) The requirements for undertaking chemical safety assessments by manufacturers and importers should be defined in detail in a technical annex to allow them to meet their obligations. To achieve fair burden sharing with their customers, manufacturers and importers should in their chemical safety assessment address not only their own uses and the uses for which they place their substances on the market, but also all uses which their customers ask them to address.
(31) The Commission, in close cooperation with industry, Member States and other relevant stakeholders, should develop guidance to fulfil the requirements under this Regulation related to M3 mixtures (in particular with regard to safety data sheets incorporating exposure scenarios) including assessment of substances incorporated into special M3 mixtures — such as metals incorporated in alloys. In doing so, the Commission should take full account of the work that will have been carried out within the framework of the RIPs and should include the necessary guidance on this matter in the overall REACH guidance package. This guidance should be available before the application of this Regulation.
(32) A chemical safety assessment should not need to be performed for substances in M3 mixtures in certain very small concentrations which are considered as not giving rise to concern. Substances in M3 mixtures in such low concen trations should also be exempt from authorisation. These provisions should apply equally to M3 mixtures that are solid mixtures of substances until a specific shape is given to such a M3 mixture that transforms it into an article.
(33) Joint submission and the sharing of information on substances should be provided for in order to increase the efficiency of the registration system, to reduce costs and to reduce testing on vertebrate animals. One of a group of multiple registrants should submit information on behalf of the others according to rules which ensure that all the required information is submitted, while allowing sharing of the costs burden. A registrant should be able to submit information directly to the Agency in certain specified cases.
(34) Requirements for generation of information on substances should be tiered according to the volumes of manufacture or importation of a substance, because these provide an indication of the potential for exposure of man and the environment to the substances, and should be described in detail. To reduce the possible impact on low volume substances, new toxicological and ecotoxicological information should only be required for priority substances between 1 and 10 tonnes. For other substances in that quantity range there should be incentives to encourage manufacturers and importers to provide this information.
(35) The Member States, the Agency and all interested parties should take full account of the results of the RIPs, in particular with regard to the registration of substances which occur in nature.
(36) It is necessary to consider the application of Article 2(7)(a) and (b) and Annex XI to substances derived from mineralogical processes and the review of Annexes IV and V should fully take this into account.
(37) If tests are performed, they should comply with the relevant requirements of protection of laboratory animals, set out in Council Directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes 1, and, in the case of ecotoxicological and toxicological tests, good laboratory practice, set out in Directive 2004/10/EC of the European Parliament and of the Council of 11 February 2004 on the harmonisation of laws, regulations and administrative provisions relating to the appli cation of the principles of good laboratory practice and the veri fication of their application for tests on chemical substances 2.
(38) The generation of information by alternative means offering equivalence to prescribed tests and test methods should also be allowed, for example when this information comes from valid qualitative or quantitative structure activity models or from struc turally related substances. To this end the Agency, in cooperation with Member States and interested parties, should develop appro priate guidance. It should also be possible not to submit certain information if appropriate justification can be provided. Based on experience gained through RIPs, criteria should be developed defining what constitutes such justification.
(39) In order to help companies, and in particular SMEs, to comply with the requirements of this Regulation, Member States, in addition to the operational guidance documents provided by the Agency, should establish national helpdesks.
(40) The Commission, Member States, industry and other stakeholders should continue to contribute to the promotion of alternative test methods on an international and national level including computer supported methodologies, in vitro methodologies, as appropriate, those based on toxicogenomics, and other relevant methodologies. The Community's strategy to promote alternative test methods is a priority and the Commission should ensure that within its future Research Framework Programmes and initiatives such as the Community Action Plan on the Protection and Welfare of Animals 2006 to 2010 this remains a priority topic. Participation of stakeholders and initiatives involving all interested parties should be sought.
(41) For reasons of workability and because of their special nature, specific registration requirements should be laid down for inter mediates. Polymers should be exempted from registration and evaluation until those that need to be registered due to the risks posed to human health or the environment can be selected in a practicable and cost-efficient way on the basis of sound technical and valid scientific criteria.
(42) To avoid overloading authorities and natural or legal persons with the work arising from the registration of phase-in substances already on the internal market, that registration should be spread over an appropriate period of time, without introducing undue delay. Deadlines for the registration of these substances should therefore be set.
(43) Data for substances already notified in accordance with Directive 67/548/EEC should be eased into the system and should be upgraded when the next tonnage quantity threshold is reached.
(44) In order to provide a harmonised, simple system, all registrations should be submitted to the Agency. To ensure a consistent approach and efficient use of resources, it should perform a completeness check on all registrations and take responsibility for any final rejections of registrations.
(45) The European Inventory of Existing Commercial Chemical Substances (EINECS) included certain complex substances in a single entry. UVCB substances (substances of unknown or variable composition, complex reaction products or biological materials) may be registered as a single substance under this Regulation, despite their variable composition, provided that the hazardous properties do not differ significantly and warrant the same classification.
(46) To ensure that the information gathered through the registration is kept up-to-date, an obligation on registrants to inform the Agency of certain changes to the information should be introduced.
(47) In accordance with Directive 86/609/EEC, it is necessary to replace, reduce or refine testing on vertebrate animals. Implemen tation of this Regulation should be based on the use of alternative test methods, suitable for the assessment of health and environ mental hazards of chemicals, wherever possible. The use of animals should be avoided by recourse to alternative methods validated by the Commission or international bodies, or recognised by the Commission or the Agency as appropriate to meet the information requirements under this Regulation. To this end, the Commission, following consultation with relevant stake holders, should propose to amend the future Commission Regu lation on test methods or this Regulation, where appropriate, to replace, reduce or refine animal testing. The Commission and the Agency should ensure that reduction of animal testing is a key consideration in the development and maintenance of guidance for stakeholders and in the Agency's own procedures.
(48) This Regulation should be without prejudice to the full and complete application of the Community competition rules.
(49) In order to avoid duplication of work, and in particular to reduce testing involving vertebrate animals, the provisions concerning preparation and submission of registrations and updates should require sharing of information where this is requested by any registrant. If the information concerns vertebrate animals, the registrant should be obliged to request it.
(50) It is in the public interest to ensure the quickest possible circu lation of test results on human health or environmental hazards of certain substances to those natural or legal persons which use them, in order to limit any risks associated with their use. Sharing of information should occur where this is requested by any registrant, in particular in the case of information involving tests on vertebrate animals, under conditions that ensure a fair compensation for the company that has undertaken the tests.
(51) In order to strengthen the competitiveness of Community industry and to ensure that this Regulation is applied as efficiently as possible, it is appropriate to make provision for the sharing of data between registrants on the basis of fair compensation.
(52) In order to respect the legitimate property rights of those generating testing data, the owner of such data should, for a period of 12 years, be able to claim compensation from those registrants who benefit from that data.
(53) In order to allow a potential registrant of a phase-in substance to proceed with his registration, even if he cannot reach agreement with a previous registrant, the Agency, on request, should allow use of any summary or robust study summary of tests already submitted. The registrant who receives these data should be obliged to pay a contribution to the costs to the owner of the data. For non-phase-in substances, the Agency may ask for evidence that a potential registrant has paid the owner of a study before the Agency gives permission for the potential registrant to use that information in his registration.
(54) In order to avoid duplication of work, and in particular to avoid duplication of testing, registrants of phase-in substances should pre-register as early as possible with a database managed by the Agency. A system should be established in order to provide for the establishment of Substance Information Exchange Forums (SIEF) to help exchange of information on the substances that have been registered. SIEF participants should include all relevant actors submitting information to the Agency on the same phase-in substance. They should include both potential registrants, who must provide and be supplied with any information relevant to the registration of their substances, and other participants, who may receive financial compensation for studies they hold but are not entitled to request information. In order to ensure the smooth functioning of that system they should fulfil certain obligations. If a member of a SIEF does not fulfil his obligations, he should be penalised accordingly but other members should be enabled to continue preparing their own registration. In cases where a substance has not been pre-registered, measures should be taken to help downstream users find alternative sources of supply.
(55) Manufacturers and importers of a substance on its own or in a M3 mixture should be encouraged to communicate with the downstream users of the substance with regard to whether they intend to register the substance. Such information should be provided to a downstream user sufficiently in advance of the relevant registration deadline if the manufacturer or importer does not intend to register the substance, in order to enable the downstream user to look for alternative sources of supply.
(56) Part of the responsibility of manufacturers or importers for the management of the risks of substances is the communication of information on these substances to other professionals such as downstream users or distributors. In addition, producers or importers of articles should supply information on the safe use of articles to industrial and professional users, and consumers on request. This important responsibility should also apply throughout the supply chain to enable all actors to meet their responsibility in relation to management of risks arising from the use of substances.
(57) As the existing safety data sheet is already being used as a communication tool within the supply chain of substances and M3 mixtures , it is appropriate to develop it further and make it an integral part of the system established by this Regu lation.
(58) In order to have a chain of responsibilities, downstream users should be responsible for assessing the risks arising from their uses of substances if those uses are not covered by a safety data sheet received from their suppliers, unless the downstream user concerned takes more protective measures than those recom mended by his supplier or unless his supplier was not required to assess those risks or provide him with information on those risks. For the same reason, downstream users should manage the risks arising from their uses of substances. In addition, it is appropriate that any producer or importer of an article containing a substance of very high concern should provide sufficient infor mation to allow safe use of such an article.
(59) The requirements for undertaking chemical safety assessments by downstream users should also be prescribed in detail to allow them to meet their obligations. These requirements should only apply above a total quantity of one tonne of substance or M3 mixture . In any case, however, the downstream users should consider the use and identify and apply appropriate risk management measures. Downstream users should report certain basic information on use to the Agency.
(60) For enforcement and evaluation purposes, downstream users of substances should be required to report to the Agency certain basic information if their use is outside the conditions of the exposure scenario detailed in the safety data sheet communicated by their original manufacturer or importer and to keep such reported information up-to-date.
(61) For reasons of workability and proportionality, it is appropriate to exempt downstream users using low quantities of a substance from such reporting.
(62) Communication up and down the supply chain should be facilitated. The Commission should develop a system categorising brief general descriptions of uses taking into account the outcomes of the RIPs.
(63) It is also necessary to ensure that generation of information is tailored to real information needs. To this end evaluation should require the Agency to decide on the programmes of testing proposed by manufacturers and importers. In cooperation with Member States, the Agency should give priority to certain substances, for instance those which may be of very high concern.
(64) In order to prevent unnecessary animal testing, interested parties should have a period of 45 days during which they may provide scientifically valid information and studies that address the relevant substance and hazard end-point, which is addressed by the testing proposal. The scientifically valid information and studies received by the Agency should be taken into account for decisions on testing proposals.
(65) In addition, it is necessary to instil confidence in the general quality of registrations and to ensure that the public at large as well as all stakeholders in the chemicals industry have confidence that natural or legal persons are meeting the obligations placed upon them. Accordingly, it is appropriate to provide for recording which information has been reviewed by an assessor possessing appropriate experience, and for a percentage of registrations to be checked for compliance by the Agency.
(66) The Agency should also be empowered to require further infor mation from manufacturers, importers or downstream users on substances suspected of posing a risk to human health or the environment, including by reason of their presence on the internal market in high volumes, on the basis of evaluations performed. Based on the criteria for prioritising substances developed by the Agency in cooperation with the Member States a Community rolling action plan for substance evaluation should be established, relying on Member State competent auth orities to evaluate substances included therein. If a risk equivalent to the level of concern arising from the use of substances subject to authorisation arises from the use of isolated intermediates on site, the competent authorities of the Member States should also be allowed to require further information, when justified.
(67) Collective agreement within the Agency's Member State Committee on its draft decisions should provide the basis for an efficient system that respects the principle of subsidiarity, while maintaining the internal market. If one or more Member States or the Agency do not agree to a draft decision, it should be adopted subject to a centralised procedure. If the Member State Committee fails to reach unanimous agreement, the Commission should adopt a decision in accordance with a Committee procedure.
(68) Evaluation may lead to the conclusion that action should be taken under the restriction or authorisation procedures or that risk management action should be considered in the framework of other appropriate legislation. Information on the progress of evaluation proceedings should therefore be made public.
(69) To ensure a sufficiently high level of protection for human health, including having regard to relevant human population groups and possibly to certain vulnerable sub-populations, and the environ ment, substances of very high concern should, in accordance with the precautionary principle, be subject to careful attention. Auth orisation should be granted where natural or legal persons applying for an authorisation demonstrate to the granting authority that the risks to human health and the environment arising from the use of the substance are adequately controlled. Otherwise, uses may still be authorised if it can be shown that the socio-economic benefits from the use of the substance outweigh the risks connected with its use and there are no suitable alter native substances or technologies that are economically and tech nically viable. Taking into account the good functioning of the internal market it is appropriate that the Commission should be the granting authority.
(70) Adverse effects on human health and the environment from substances of very high concern should be prevented through the application of appropriate risk management measures to ensure that any risks from the uses of a substance are adequately controlled, and with a view to progressively substituting these substances with a suitable safer substance. Risk management measures should be applied to ensure, when substances are manu factured, placed on the market and used, that exposure to these substances including discharges, emissions and losses, throughout the whole life-cycle is below the threshold level beyond which adverse effects may occur. For any substance for which author isation has been granted, and for any other substance for which it is not possible to establish a safe level of exposure, measures should always be taken to minimise, as far as technically and practically possible, exposure and emissions with a view to mini mising the likelihood of adverse effects. Measures to ensure adequate control should be identified in any Chemical Safety Report. These measures should be applied and, where appro priate, recommended to other actors down the supply chain.
(71) Methodologies to establish thresholds for carcinogenic and mutagenic substances may be developed taking into account the outcomes of RIPs. The relevant Annex may be amended on the basis of these methodologies to allow thresholds where appro priate to be used while ensuring a high level of protection of human health and the environment.
(72) To support the aim of eventual replacement of substances of very high concern by suitable alternative substances or technologies, all applicants for authorisation should provide an analysis of alternatives considering their risks and the technical and economic feasibility of substitution, including information on any research and development the applicant is undertaking or intends to undertake. Furthermore, authorisations should be subject to time-limited review whose periods would be determined on a case-by-case basis and normally be subject to conditions, including monitoring.
(73) Substitution of a substance on its own, in a M3 mixture or in an article should be required when manufacture, use or placing on the market of that substance causes an unacceptable risk to human health or to the environment, taking into account the availability of suitable safer alternative substances and tech nologies, and the socio-economic benefits from the uses of the substance posing an unacceptable risk.
(74) Substitution of a substance of very high concern by suitable safer alternative substances or technologies should be considered by all those applying for authorisations of uses of such substances on their own, in M3 mixtures or for incorporation of substances into articles by making an analysis of alternatives, the risks involved in using any alternative and the technical and economic feasibility of substitution.
(75) The possibility of introducing restrictions on the manufacturing, placing on the market and use of dangerous substances, M3 mixtures and articles applies to all substances falling within the scope of this Regulation, with minor exemptions. Restrictions on the placing on the market and the use of substances which are carcinogenic, mutagenic or toxic to repro duction, category 1 or 2, for their use by consumers on their own or in M3 mixtures should continue to be introduced.
(76) Experience at international level shows that substances with characteristics rendering them persistent, liable to bioaccumulate and toxic, or very persistent and very liable to bioaccumulate, present a very high concern, while criteria have been developed allowing the identification of such substances. For certain other substances concerns are sufficiently high to address them in the same way on a case-by-case basis. The criteria in Annex XIII should be reviewed taking into account the current and any new experience in the identification of these substances and if appro priate, be amended with a view to ensuring a high level of protection for human health and the environment.
(77) In view of workability and practicality considerations, both as regards natural or legal persons, who have to prepare application files and take appropriate risk management measures, and as regards the authorities, who have to process authorisation appli cations, only a limited number of substances should be subjected to the authorisation procedure at the same time and realistic deadlines should be set for applications, while allowing certain uses to be exempted. Substances identified as meeting the criteria for authorisation should be included in a candidate list for eventual inclusion in the authorisation procedure. Within this list, substances on the Agency's work programme should be clearly identified.
(78) The Agency should provide advice on the prioritisation of substances to be made subject to the authorisation procedure, to ensure that decisions reflect the needs of society as well as scientific knowledge and developments.
(79) A total ban on a substance would mean that none of its uses could be authorised. It would therefore be pointless to allow the submission of applications for authorisation. In such cases the substance should be removed from the list of substances for which applications can be submitted and added to the list of restricted substances.
(80) The proper interaction between the provisions on authorisation and restriction should be ensured in order to preserve the efficient functioning of the internal market and the protection of human health, safety and the environment. Restrictions that exist when the substance in question is added to the list of substances for which applications for authorisation can be submitted, should be maintained for that substance. The Agency should consider whether the risk from substances in articles is adequately controlled and, if it is not, prepare a dossier in relation to introduction of further restrictions for substances for which the use requires authorisation.
(81) In order to provide a harmonised approach to the authorisation of the uses of particular substances, the Agency should issue opinions on the risks arising from those uses, including whether or not the substance is adequately controlled and on any socio-economic analysis submitted to it by third parties. These opinions should be taken into account by the Commission when considering whether or not to grant an authorisation.
(82) To allow effective monitoring and enforcement of the authoris ation requirement, downstream users benefiting from an author isation granted to their supplier should inform the Agency of their use of the substance.
(83) It is suitable in these circumstances that final decisions granting or refusing authorisations be adopted by the Commission pursuant to a regulatory procedure in order to allow for an exa mination of their wider implications within the Member States and to associate the latter more closely with the decisions.
(84) In order to accelerate the current system the restriction procedure should be restructured and Directive 76/769/EEC, which has been substantially amended and adapted several times, should be replaced. In the interests of clarity and as a starting point for this new accelerated restriction procedure, all the restrictions developed under that Directive should be incorporated into this Regulation. Where appropriate, the application of Annex XVII of this Regulation should be facilitated by guidance developed by the Commission.
(85) In relation to Annex XVII Member States should be allowed to maintain for a transitional period more stringent restrictions, provided that these restrictions have been notified according to the Treaty. This should concern substances on their own, substances in M3 mixtures and substances in articles, the manufacturing, the placing on the market and the use of which is restricted. The Commission should compile and publish an inventory of these restrictions. This would provide an opportunity for the Commission to review the measures concerned with a view to possible harmonisation.
(86) It should be the responsibility of the manufacturer, importer and downstream user to identify the appropriate risk management measures needed to ensure a high level of protection for human health and the environment from the manufacturing, placing on the market or use of a substance on its own, in a M3 mixture or in an article. However, where this is considered to be insufficient and where Community legislation is justified, appropriate restrictions should be laid down.
(87) In order to protect human health and the environment, restrictions on the manufacture, placing on the market or use of a substance on its own, in a M3 mixture or in an article may include any condition for, or prohibition of, the manufacture, placing on the market or use. Therefore it is necessary to list such restrictions and any amendments thereto.
(88) In order to prepare a restrictions proposal and in order for such legislation to operate effectively, there should be good cooper ation, coordination and information between the Member States, the Agency, other bodies of the Community, the Commission and the interested parties.
(89) In order to give Member States the opportunity to submit proposals to address a specific risk for human health and the environment, they should prepare a dossier in conformity with detailed requirements. The dossier should set out the justification for Community-wide action.
(90) In order to provide a harmonised approach to restrictions, the Agency should fulfil a role as coordinator of this procedure, for example by appointing the relevant rapporteurs and verifying conformity with the requirements of the relevant Annexes. The Agency should maintain a list of substances for which a restriction dossier is being prepared.
(91) In order to give the Commission the opportunity to address a specific risk for human health and the environment that needs to be addressed Community wide, it should be able to entrust the Agency with the preparation of a restriction dossier.
(92) For reasons of transparency, the Agency should publish the relevant dossier including the suggested restrictions while requesting comments.
(93) In order to finalise the procedure in due time, the Agency should submit its opinions on the suggested action and its impact on the basis of a draft opinion prepared by a rapporteur.
(94) In order to speed up the procedure for restrictions, the Commission should prepare its draft amendment within a specific time limit of receiving the Agency's opinions.
(95) The Agency should be central to ensuring that chemicals legis lation and the decision-making processes and scientific basis underlying it have credibility with all stakeholders and the public. The Agency should also play a pivotal role in coordi nating communication around this Regulation and in its im plementation. The confidence in the Agency of the Community institutions, the Member States, the general public and interested parties is therefore essential. For this reason, it is vital to ensure its independence, high scientific, technical and regulatory capa cities, as well as transparency and efficiency.
(96) The structure of the Agency should be suitable for the tasks that it should fulfil. Experience with similar Community agencies provides some guidance in this respect but the structure should be adapted to meet the specific needs of this Regulation.
(97) The effective communication of information on chemical risks and how they can be managed is an essential part of the system established by this Regulation. Best practice from the chemicals and other sectors should be considered in the preparation of guidance by the Agency to all stakeholders.
(98) In the interests of efficiency, the staff of the Agency Secretariat should perform essentially technical-administrative and scientific tasks without calling on the scientific and technical resources of the Member States. The Executive Director should ensure the efficient execution of the Agency's tasks in an independent manner. To ensure that the Agency fulfils its role, the compo sition of the Management Board should be designed to represent each Member State, the Commission and other interested parties appointed by the Commission in order to ensure the involvement of stakeholders, and the European Parliament and to secure the highest standard of competence and a broad range of relevant expertise in chemicals safety or the regulation of chemicals, whilst ensuring that there is relevant expertise in the field of general financial and legal matters.
(99) The Agency should have the means to perform all the tasks required to carry out its role.
(100) A Commission Regulation should specify the structure and amounts of fees, including specifying the circumstances under which a proportion of the fees will be transferred to the relevant Member State competent authority.
(101) The Management Board of the Agency should have the necessary powers to establish the budget, check its implementation, draw up internal rules, adopt financial regulations and appoint the Executive Director.
(102) Through a Committee for Risk Assessment and a Committee for Socio-economic Analysis, the Agency should take over the role of the Scientific Committees attached to the Commission in issuing scientific opinions in its field of competence.
(103) Through a Member State Committee, the Agency should aim to reach agreement amongst Member States' authorities on specific issues which require a harmonised approach.
(104) It is necessary to ensure close cooperation between the Agency and the competent authorities working within the Member States so that the scientific opinions of the Committee for Risk Assessment and the Committee for Socio-economic Analysis are based on the broadest possible scientific and technical expertise appropriate which is available within the Community. To the same end, these Committees should be able to rely on additional particular expertise.
(105) In the light of the increased responsibility of natural or legal persons for ensuring safe use of chemicals, enforcement needs to be strengthened. The Agency should therefore provide a Forum for Member States to exchange information on and to coordinate their activities related to the enforcement of chemicals legislation. The currently informal cooperation between Member States in this respect would benefit from a more formal framework.
(106) A Board of Appeal should be set up within the Agency to guarantee processing of appeals for any natural or legal person affected by decisions taken by the Agency.
(107) The Agency should be financed partly by fees paid by natural or legal persons and partly by the general budget of the European Communities. The Community budgetary procedure should remain applicable as far as any subsidies chargeable to the general budget of the European Communities are concerned. Moreover, the auditing of accounts should be undertaken by the Court of Auditors in accordance with Article 91 of Commission Regulation (EC, Euratom) No 2343/2002 of 23 December 2002 on the framework Financial Regulation for the bodies referred to in Article 185 of Council Regulation (EC, Euratom) No 1605/2002 on the Financial Regulation applicable to the general budget of the European Communities (1).
(108) Where the Commission and Agency consider it appropriate, it should be possible for representatives of third countries to parti cipate in the work of the Agency.
(109) The Agency should contribute, through cooperation with organ isations having interests in the harmonisation of international regulations, to the role of the Community and the Member States in such harmonisation activities. To promote broad inter national consensus the Agency should take account of existing and emerging international standards in the regulation of chemicals such as the Globally Harmonised System (GHS) of classification and labelling of chemicals.
(110) The Agency should provide the infrastructure needed for natural or legal persons to meet their obligations under the data-sharing provisions.
(111) It is important to avoid confusion between the mission of the Agency and the respective missions of the European Medicines Agency (EMEA) established by Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency 1, the European Food Safety Authority (EFSA) established by Regulation (EC) No 178/2002 of the European Parliament and of the Council of
28 January 2002 laying down the general principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in matters of food safety 2 and the Advisory Committee on Safety, Hygiene and Health Protection at Work set up by the Council Decision of
22 July 2003 3. Consequently, the Agency should establish rules of procedure where cooperation with the EFSA or the Advisory Committee on Safety, Hygiene and Health Protection at Work is necessary. This Regulation should otherwise be without prejudice to the competence conferred on the EMEA, the EFSA and the Advisory Committee on Safety, Hygiene and Health Protection at Work by Community legislation.
(112) In order to achieve the functioning of the internal market for substances on their own or in M3 mixtures , while at the same time ensuring a high level of protection for human health and the environment, rules should be established for a classifi cation and labelling inventory.
(113) The classification and labelling for any substance either subject to registration or covered by Article 1 of Directive 67/548/EEC and placed on the market should therefore be notified to the Agency to be included in the inventory.
(114) To ensure a harmonised protection for the general public, and, in particular, for persons who come into contact with certain substances, and the proper functioning of other Community legis lation relying on the classification and labelling, an inventory should record the classification in accordance with Directive 67/548/EEC and Directive 1999/45/EC agreed by manufacturers and importers of the same substance, if possible, as well as decisions taken at Community level to harmonise the classifi cation and labelling of some substances. This should take full account of the work and experience accumulated in connection with the activities under Directive 67/548/EEC, including the classification and labelling of specific substances or groups of substances listed in Annex I of Directive 67/548/EEC.
1 OJ C 112, 30.4.2004, p. 92 and OJ C 294, 25.11.2005, p. 38.
2 OJ C 164, 5.7.2005, p. 78.
3 Opinion of the European Parliament of 17 November 2005 (OJ C 280 E, 18.11.2006, p. 303), Council Common Position of 27 June 2006 (OJ C 276 E, 14.11.2006, p. 1) and Position of the European Parliament of 13 December 2006 (not yet published in the Official Journal). Council Decision of 18 December 2006.
1 OJ 196, 16.8.1967, p. 1. Directive as last amended by Commission Directive 2004/73/EC (OJ L 152, 30.4.2004, p. 1). Corrected in OJ L 216, 16.6.2004, p. 3.
2 OJ L 262, 27.9.1976, p. 201. Directive as last amended by Commission Directive 2006/139/EC (OJ L 384, 29.12.2006, p. 94).
3 OJ L 200, 30.7.1999, p. 1. Directive as last amended by Commission Directive 2006/8/EC (OJ L 19, 24.1.2006, p. 12).
4 OJ L 84, 5.4.1993, p. 1. Regulation as amended by Regulation (EC) No 1882/2003 of the European Parliament and of the Council (OJ L 284, 31.10.2003, p. 1).
1 OJ L 158, 30.4.2004, p. 50, corrected in OJ L 229, 29.6.2004, p. 23.
2 OJ L 131, 5.5.1998, p. 11.
3 OJ L 262, 27.9.1976, p. 169. Directive as last amended by Commission Directive 2007/1/EC (OJ L 25, 1.2.2007, p. 9).
1 OJ L 358, 18.12.1986, p. 1. Directive as amended by Directive 2003/65/EC of the European Parliament and of the Council (OJ L 230, 16.9.2003, p. 32).
2 OJ L 50, 20.2.2004, p. 44.
1 OJ L 357, 31.12.2002, p. 72.
(1) OJ L 136, 30.4.2004, p. 1. Regulation as amended by Regulation (EC) No 1901/2006 (OJ L 378, 27.12.2006, p. 1).
2 OJ L 31, 1.2.2002, p. 1. Regulation as last amended by Commission Regu lation (EC) No 575/2006 (OJ L 100, 8.4.2006, p. 3).
3 OJ C 218, 13.9.2003, p. 1.